Adapting Eligibility Criteria for Prescribing FDA Approved Anti-Amyloid Immunotherapeutics for Adults with Down Syndrome with Early-Stage Alzheimer’s Dementia (Statement)

An Advisory and Consensus Statement of the Working Group on Criteria for Access to Alzheimer’s Therapeutics for Adults with Down Syndrome; experts were convened to determine prescribing criteria equivalences that would be inclusionary of adults with Down syndrome. This advisory and consensus statement is the result of the experts’ deliberations and recommendations for addressing this inequity to treatment access and includes alternative inclusionary language and modified criteria, as well as providing a roadmap for prescribers when determining eligibility for adults with Down syndrome.